Clinical Trial Update: Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating safety and tolerability of a regimen combining low-dose radiotherapy, sugemalimab, chemotherapy, and olaparib as first-line …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer
• Lung Cancer

Drugs mentioned

• Chemotherapy (unspecified)
• Olaparib (Olaparib)
• Sugemalimab (sugemalimab)

Snippet

Sponsor: Sichuan University | Conditions: Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING